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2 N.P. Skliros et al.“Medicine is a science of uncertainty and an art of prob-
ability”1 (William Osler). As such, it has changed and will
continue to change dynamically. The first incorporation of
probability in medicine appears in the Old Testament
(605e562 B.C.) where King Nebuchadnezzar II ran the first
written trial on dietary habits and its effects on human
health.2 The Greek physician and philosopher Galen
(129e216 A.D.), who was known for his exploratory spirit,
described and used different mixtures of various minerals
and herbs on his patients, evaluating their positive and
negative effects.3 Avicenna, in The Canon of Medicine
(1025 A.D.), formed the basis of modern clinical trials,
introducing seven practical rules for the experimental use
and testing of medicines.4 In 1537, Ambroise Pare, a known
Renaissance surgeon, unintentionally carried out a trial
when he ran out of boiling oil and changed the standard
treatment for open wounds and recorded the first non-
inferiority results.5 Since then, numerous evidence-based
trials have provided health-care professionals with
reasoning and confidence in everyday practice. The effects
of oral antidiabetic drugs for type 2 diabetes mellitus
(T2DM) on cardiovascular (CV) risk is a continuously
evolving matter that needs multiple confirmations from
trials because of its multifactorial and complex nature.
According to the World Health Organization (WHO), in
1985, there were 30 million people who had diabetes
worldwide, andby 1995, therewere 135million.6 Thenumber
is presently at 387 million, and by the year 2035, it isTable 1 Types of antidiabetic drugs and mechanism of action.
Class Substance Mechanism of Action
Sulfonylureas Gliclazide
Glimepiride
Glibenclamide
Stimulate the pancr
produce more insuli
Meglitinide Nateglinide
Repaglinde
Stimulate the pancr
produce more insuli
Biguanides Metformin Reduce the product
glucose by the liver
Thiazolidinediones (TZD) Pioglitazone
Rosiglitazone
Increase insulin sens
the body cells and r
production of glucos
liver
Alpha-glucosidases
inhibitors
Acarbose Slow the absorption
carbohydrates (suga
Dipeptidyl- peptidase-4
(DPP-4) inhibitors
Linagliptin
Saxagliptin
Sitagliptin
Alogliptin
Intensify the effect
intestinal hormones
involved in the cont
sugar
Glucagon-like peptide-1
(GLP-1) agonist
Exenatide
Liraglutide
Mimic the effect of
intestinal hormones
involved in the cont
sugar
Sodium glucose co-
transporter 2
inhibitors (SGLT2)
Canagliflozin
Empagliflozin
Dapagliflozin
Help eliminate gluco
urine
Adapted from “Diabetes Que´bec”, 2015 and “ESC Guidelines on diabe
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(2016), http://dx.doi.org/10.1016/j.hjc.2016.07.002estimated to reach at least 592 million people worldwide.7,8
Type 2 diabetes mellitus, which affects more than 90% of
diabetic patients, is a metabolic disorder with a progressive
decline of pancreatic b-cell function and a biochemical pre-
sentation of impaired fasting and/or post-prandial blood
glucose levels.
One of the major complications of T2DM is cardiovas-
cular (CV) disease, and at least 68% of people >65 years
with diabetes die of heart disease.9,10 The etiology of
diabetes-derived CV complications is not clear yet, but the
underlying mechanisms are based on a complex and multi-
factorial pathophysiology that includes macrovascular,
epigenetic and intracellular metabolic changes.11e14
While a variety of categories of antidiabetic drugs (Table
1) are available to help clinicians fight the disease, the
mechanism of action and effect on end-points of the spe-
cific drug must be elucidated to decide on the appropriate
choice for a specific patient profile (Figure 1). The blood
glucose and glycated A1C hemoglobin (A1C) levels are
routinely used to monitor the effectiveness of the antidia-
betic medication and patient compliance. The target A1C
levels have been set from the American Diabetes Associa-
tion, the European Association for the Study of Diabetes,
and the International Diabetes Federation to a range be-
tween 6.5% and 7%. Reaching this target is difficult to
achieve in everyday clinical practice. However, what is
most important is whether A1C can be used as a surrogate
for CV end-points. Because the latest trials do not confirmWeight Known Side-Effects
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abetes: Crossing to the other side, Hellenic Journal of Cardiology
Figure 1 Mechanism of action of T2DM drugs.
Antidiabetic drugs and cardiovascular disease 3that the control of A1C levels in patients with T2DM has
been associated with a positive effect on macrovascular
complications, its use as a surrogate marker may have to be
re-evaluated.15
1. To CVOT or not to CVOT?
Cardiovascular outcome trials (CVOT) are the optimal way
to evaluate not only the efficacy but also the CV safety of a
drug. In past decades, especially in the 1990’s, a large
number of medical studies addressed the risk of antidia-
betic drug-induced CVD.16e20 In 1999, the American Heart
Association (AHA) confirmed, collected and published data
from these evidence-based trials in a scientific statement
entitled “Diabetes and Cardiovascular Disease”.21 Large
clinical trials highlighted the positive role of antidiabetic
drugs in lowering A1C levels and obtaining optimal glycemic
control. However, data from a number of trials showed that
antidiabetic drugs provoked heart and vessel disease,
dividing the scientific community. The most recent indica-
tive example was with the thiazolidinedione (TZD) drug,
rosiglitazone. Initial clinical trials showed that it was posi-
tively correlated with CV prevention in diabetic patients,
making it one of the top antidiabetic drugs on the market
until 2007, when a meta-analysis study22 linked rosiglita-
zone to a significant (43%) increase in risk for myocardial
infractions and an increasing trend (64%) towards CV death.
These data called into question the validity of basing dia-
betes treatment on a measurable outcome, glycemic con-
trol. The European Medicines Agency (EMA) banned the
drug, and the US Food and Drug Administration (FDA) forced
the company to add a box warning about the potential
increased risk for heart attacks. However, post-market
studies, albeit years later, did not confirm the results of
the meta-analysis for rosiglitazone. In addition, the RE-
CORD trial did not show an increase of the overall risk of CV
morbidity or mortality compared with standard glucose-
lowering drugs (with the exception of an increased risk of
heart failure hospitalization HR: 2.10, 95% CI 1.35 to 3.27),Please cite this article in press as: Skliros NP, et al., Treatment of di
(2016), http://dx.doi.org/10.1016/j.hjc.2016.07.002indicating how complex the issue of effectiveness and CV
safety of an antidiabetic drug is.23
In any case, the scene for drawing safer conclusions on
the CVD safety of antidiabetic drugs had been set. The next
step for the FDA was the 2008 publication of “Guidance for
Industry Diabetes Mellitus d Evaluating Cardiovascular
Risk in New Antidiabetic Therapies to Treat Type 2 Dia-
betes”, that demanded changes in the way T2DM drug trials
were conducted. The publication stipulated that trials had
to include special populations such as advanced disease
patients and multi-national ethnic groups, predetermined
subgroup analyses and an in-depth safety review with a
specific focus on CVD outcomes, such as stroke, myocardial
infraction and CV mortality. Finally, new limits were set on
the upper bound of the two-sided 95% confidence interval
for the estimated risk ratio to be below 1.3. For instance, it
is not reassuring to find an insignificant risk ratio of which
the upper boundary of the confidence interval is 1.5. To
gain more confidence that an increase in risk does not truly
exist, a trial must clearly show that the upper boundary of
the two sided 95% confidence interval for the estimated risk
ratio is below 1.3.24
2. Non-maleficence? No beneficence either
Following the new FDA and EMA requirements for the CV
safety of antidiabetic drugs and adhering to the Hippocratic
principle “(first) to do no harm”, several new trials (Table
2) in the last 5 years used the non-inferiority design, that
is, the drug under investigation had to be no less effective
and no more harmful than the control before it could be
introduced into the drug market. This approach may at first
appear cautious and passive. We have to emphasize, how-
ever, that in the era of a holistic therapeutic approach, it is
difficult to add therapeutic benefit with a new interven-
tion. Across time, in landmark trials including patients with
a high CV risk, the number needed to treat (NNT) to prevent
one primary event has increased from 30 (for 5.4 years) in
the pre-statin era with simvastatin, to 56 (for 5 years) in theabetes: Crossing to the other side, Hellenic Journal of Cardiology
Table 2 General data of CVOT in TD2M.
CVOT Class Generic Name Year Primary
Objective
Enrollment Population
additional
characteristics
Primary
Outcome
Primary
Outcome
Confirmation
HFH
Confirmation
Non-
inferiority
Superiority
TZD
RECORD Rosiglitazone 2008 CV outcome
vs. SoC
4447 A1C:7.0%-9.0%,
BMI>25 kg/m2
CV death or
hospitalization
HR:0.99,
CI:0.85-1.16
HR:2.10,
CI:1.35-3.27
O Not evaluated
DPP4i
EXAMINE Alogliptin 2013 MACE vs.
SoC
5380 Recent ACS,
A1C:6.5%-11.0%
CV death HR:0.96,
CI1.16
HR:1.07,
CI:0.79-1.45
O Not evaluated
SAVOR-TIMI 53 Saxagliptin 2013 CV efficacy
and safety
vs. SoC
18206 CVD,
high CV risk
CV death HR:1.00,
CI:0.89-1.12
HR:1.27,
CI:1.07-1.51
O Not proved
TECOS Sitagliptin 2015 CV outcome
vs. SoC
14724 CVD,
A1C:6.5%-8.0%
CV death or
hospitalization
HR:0.98,
CI:0.88-1.09
HR:1.00,
CI:0.83-1.20
O Not evaluated
GLP-1
ELIXA Lixisenatide 2015 CV outcome
vs. SoC
6076 ACS,
A1C:7.0%-11.0%
CV death or
hospitalization
HR:1.02,
CI:0.89-1.17
HR:0.96,
CI:0.75-1.23
O Not proved
LEADER Liraglutide 2015 CV outcome
vs. SoC
9341 Vascular
disease
Composite of
the 1st
occurrence of
CV death
HR:0.87,
CI:0.78-0.97
HR:0.87,
CI:0.73-1.05
O Proved for primary
outcome
SGLT2i
EMPA-REG
OUTCOME
Empagliflozin 2015 CV efficacy
and safety
vs. SoC
7064 High CV risk 3-point MACE HR:0.86,
CI:0.74- 0.99
HR:0.96,
CI:0.75-1.23
O Proved for CV
death, HF
hospitalization &
all-cause mortality
A1C: Glycated A1c hemoglobin, ACS: acute coronary syndrome, CV: Cardiovascular, CVD: Cardiovascular Disease, HFH: Heart Failure Hospitalization, MACE: Major Adverse Cardiac Events,
SoC: Standard of Care, T2DM: Type 2 Diabetes Mellitus
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Antidiabetic drugs and cardiovascular disease 5pre-angiotensin converting enzyme inhibitor/angiotensin
receptor blockers (ACEi/ARB) era with ramipril25,26 and
remained stable thereafter (NNT 50 for 7 years) with eze-
timibe, where over 75% of the patients receive statins and
ACEi/ARB.27 In 2013, the results of two major studies
dealing with dipeptidyl-peptidase-4 inhibitor (DPP4i) drugs
were simultaneously presented. The EXAMINE trial evalu-
ated the major CV outcomes of treatment with alogliptin
versus standard of care in patients with T2DM and recent
acute coronary syndrome. The likelihood of the primary
end point (composite death from CVD, non-fatal myocardial
infraction (MI), non-fatal stroke) was not raised in the
investigational drug arm of the trial (HR: 0.96, CI upper
boundary of one side repeated 1.16, p<0.001 for non-
inferiority). However, a trend (HR: 1.07, 95% CI 0.79 to
1.45) towards an increased risk of heart failure (HF) events
was shown.28 The SAVOR-TIMI 53 trial, assessed the CV ef-
ficacy and safety of saxagliptin on top of standard treat-
ment in patients with T2DM and showed similar results in
the rate of ischemic events (HR: 1.00, 95% CI 0.89 to 1.12,
p<0.001 for non-inferiority and pZ0.99 for superiority),
with an increase in HFH events (HR: 1.27, 95% CI 1.07 to
1.51, p<0.007).29 As shown later, the HF events occurred in
patients with chronic kidney disease (CKD) who had an
estimated glomerular filtration rate (eGFR) of <60 ml/min,
preexisting HF and an elevated baseline N-terminal pro
brain natriuretic peptide (NT-proBNP).30
Two years later, data from the TECOS and ELIXA trials
were published followed by data from the most recently
published EMPA-REG OUTCOME trial. The TECOS trial used a
non-inferiority design to assess the CV outcome of long-
term treatment with the DPP4i drug, sitagliptin used as part
of usual care compared to standard care in patients with
T2DM, a history of CVD and an A1C of 6.5% to 8.0%. The
sitagliptin-treated group was non-inferior to the control
group for primary composite CV outcomes (HR: 0.98, 95% CI
0.88 to 1.09, p<0.001). There was no difference in the
heart failure hospitalization rate between the two groups
(HR: 1.00, 95% CI: 0.83 to 1.20, pZ0.98).31 The ELIXA study,
on the other hand, evaluated the CV outcomes of the GLP-1
drug, lixisenatide, compared to a placebo in patients with
T2DM after an acute coronary syndrome (i.e., MI in the last
180 days as ST-segment elevation myocardial infraction
(STEMI), non-STEMI or unstable angina) and A1C values
between 7.0%-11.0%. Once again, the drug group was non-
inferior in comparison to the control group for the pri-
mary outcome of a CV event (HR: 1.02, 95% CI: 0.89 to 1.17)
and also for HFH (HR: 0.96, 95% CI: 0.75 to 1.23). No su-
periority was seen in reducing CV events.32
The prioritization that puts emphasis first on non-
inferiority and not on superiority started to change with the
recent trial, EMPA-REG OUTCOME. This study assessed the
safety of the sodium glucose co-transporter 2 inhibitor
(SGLT2i) drug, empagliflozin, in addition to the standard of
care for patients with T2DM and high CV risk (established
CVD). The primary outcome was a 3-point major adverse
cardiac event (MACE) and the key secondary outcome was a
4-point MACE, both using the non-inferiority and the superi-
ority design. The empagliflozin-treated group of patients was
split into two subgroups: one treated with 10 mg and the
other with 25 mg of empagliflozin. Data from both groups
showed a great reduction in A1C levels, weight and systolicPlease cite this article in press as: Skliros NP, et al., Treatment of di
(2016), http://dx.doi.org/10.1016/j.hjc.2016.07.002blood pressure (SBP) and had similar results. They were non-
inferior in comparison to the control group for the primary
outcome of a 3-point MACE (HR: 0.86, 95% CI 0.74 to 0.99,
p<0.0382), the secondary outcome of a 4-point MACE (HR:
0.89, 95% CI 0.78 to 1.01) and also for HFH (HR: 0.96, 95% CI
0.75 to 1.23). Superiority of the drug was evidenced by a 38%
reduction in CV death (HR: 0.62, 95% CI 0.49 to 0.77,
p<0.0001), a 35% reduction in HFH (HR: 0.65, 95% CI 0.50 to
0.85, p<0.0017) and a 32% reduction in all-cause mortality
(HR: 0.68, 95% CI 0.57 to 0.82, p<0.0001).33 Interestingly, the
NNTwith empagliflozin was just 39 (for 3 years).25,26
Superiority seems to be the new trend to T2DM trials
fulfilling the demands of the worldwide drug organizations.
This seems to be the case with the LEADER trial (results
published on July 28, 2016), which evaluates the CV
outcome of the glucagon-like peptide-1 (GLP-1) drug lir-
aglutide versus placebo, added to standard of care treat-
ment. The composite outcome of the first occurrence of CV
death, non-fatal MI or non-fatal stroke was set as the pri-
mary endpoint of the study. Among patients in the liraglu-
tide group, there were significantly lower occurrences of
the primary outcome (HR: 0.87, 95% CI 0.78 to 0.97
[P<0.001 for non-inferiority and PZ0.01 for superiority]).
While there were fewer deaths from CV causes in the lir-
aglutide group (HR: 0.78, 95% CI 0.66 to 0.93), the rates of
HFH were not significantly lower in the liraglutide group.373. Shaping the future
There is still much to be learned and much to be recon-
sidered. DPP4 inhibitors are gradually being regarded as an
important, alternative second line agent to the currently
preferred sulfonylurea drugs (SU) for T2DM. The CAROLINA
trial is testing the effectiveness and safety of linagliptin, a
DPP4 inhibitor drug compared with the SU drug, glime-
piride. Because the CAROLINA trial has no placebo group,
the CARMELINA trial is simultaneously evaluating the drug
versus placebo over standard of care. The CARMELINA trial
is investigating the long-term impact of linagliptin treat-
ment on CV morbidity, mortality and renal function in pa-
tients with T2DM. The primary objective is to show non-
inferiority of linagliptin with respect to time to first
occurrence of the primary composite endpoint. If non-
inferiority is ultimately shown, then the primary and renal
endpoints will be tested for superiority.35 The CAROLINA
trial, on the other hand, is investigating the long-term
impact of treatment in patients with T2DM at an elevated
CV risk on CV morbidity, mortality, relevant efficacy pa-
rameters (e.g., glycemic parameters) and safety (e.g.,
weight and hypoglycemia). The primary objective is to
show non-inferiority of linagliptin in comparison to glime-
piride as a monotherapy or as an add-on therapy, with
respect to the time to first occurrence of the primary
composite endpoint (CV death, non-fatal stroke, non-fatal
MI and hospitalization for unstable angina). If non-
inferiority with a margin of 1.3 is shown, then the primary
composite endpoint will be tested for superiority.36 Results
are to be published after 2018.
In keeping with the growing interest in SGLT2i action,
the DECLARE-TIMI 58 and CANVAS trials are also of interest.
DECLARE-TIMI 58 is investigating the effect of dapagliflozinabetes: Crossing to the other side, Hellenic Journal of Cardiology
6 N.P. Skliros et al.versus placebo in reducing CV events (MI, heart attack,
ischemic stroke and CV related death), when added to
current anti-diabetes therapy. It has a superiority hypoth-
esis, testing whether it reduces the incidence of the com-
posite endpoint of CV events over the long-term for a
median follow-up of 4.5 years. Results will be presented by
the fall of 2019.34 The CANVAS trial is using the non-
inferiority hypothesis followed by testing for superiority38
to assess the effect of canagliflozin versus placebo on the
treatment of patients with T2DM by evaluating CV risk for
MACE. Results are expected by the end of 2017.
The TOSCA.IT trial, by the Italian Society of Diabetology,
is investigating the efficacy and side effects of TZDs over
SUs, or vice versa, on reducing CV risk. It is the first study
after PROactive, to investigate the CV effects of TZDs. It
compares the impact of pioglitazone versus SUs as add-on
drugs on CVD in patients inadequately controlled with
metformin. The primary outcome is a composite of all-
cause mortality, nonfatal MI, nonfatal stroke, and un-
planned coronary revascularization, while the main sec-
ondary outcome is a composite of sudden death, MI (fatal
and nonfatal), stroke (fatal and nonfatal) and vascular in-
terventions. Results are anticipated by 2018.39
Finally, regarding GLP-1s, exenatide is being tested in the
EXSCEL trial, which is evaluating CV outcomes after treat-
ment in patients with T2DM. Data are expected by the end of
2018. The trial is comparing the effect of once weekly
exenatide as an add-on to usual care versus placebo on
reducing major CV outcomes (CV related death, nonfatal MI,
or nonfatal stroke) in patients with T2DM with a broad range
of CV risk and will also provide long-term safety information.
The primary efficacy hypothesis is that exenatide once-
weekly is superior to usual care with respect to the primary
composite CV end point, and the primary safety hypothesis
is that exenatide once-weekly is non-inferior to usual care
with respect to the primary CV composite end point.40
4. Conclusions
Diabetes is a multifactorial, multidimensional disease that
affects the entire body. The mechanisms that cause its
overall harmful effects, especially in the heart and vessels,
remain undiscovered.
Until recently, trials for T2DM drugs were primarily
focused on proving no harm before obtaining market
approval. The scientific world approached new medications
with caution rather than expectation. We are now crossing
from this necessary era of ensuring the safety of a drug to
the other side, where proof of positive effects is the
mainstay. Ongoing and future trials aim at evaluating the
risk and the benefit of oral agents; they incorporate bigger,
heterogeneous, multinational populations and high CV-risk
patients, and they take into account comorbidities, de-
mographic and cultural differences. The motto of the new
trials is a paraphrase of the Hippocratic dictum: “do no
harm, but also do some good”.
Recent and ongoing, robustly executed trials will define
the optimal drug combinations required to fight the after-
math of diabetes on the heart and its vessels. Individuali-
zation of therapy, tailored to the patient’s specific profile,
may prove to be the ultimate solution.Please cite this article in press as: Skliros NP, et al., Treatment of di
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